197 related articles for article (PubMed ID: 24407733)
1. Effects of the estrogen receptor antagonist fulvestrant on F344 rat prolactinoma models.
Cao L; Gao H; Gui S; Bai G; Lu R; Wang F; Zhang Y
J Neurooncol; 2014 Feb; 116(3):523-31. PubMed ID: 24407733
[TBL] [Abstract][Full Text] [Related]
2. The Wnt/β-catenin signaling pathway is involved in the antitumor effect of fulvestrant on rat prolactinoma MMQ cells.
Cao L; Gao H; Li P; Gui S; Zhang Y
Tumour Biol; 2014 Jun; 35(6):5121-7. PubMed ID: 24643679
[TBL] [Abstract][Full Text] [Related]
3. Effects of estrogen receptor antagonist on biological behavior and expression of growth factors in the prolactinoma MMQ cell line.
Lv H; Li C; Gui S; Sun M; Li D; Zhang Y
J Neurooncol; 2011 Apr; 102(2):237-45. PubMed ID: 20700755
[TBL] [Abstract][Full Text] [Related]
4. Suppression of MMQ cells by fulvestrant: possible mechanism of action and potential application for bromocriptine-resistant prolactinomas.
Bai J; Gui S; Zhang Y
J Clin Neurosci; 2013 May; 20(5):721-5. PubMed ID: 23523357
[TBL] [Abstract][Full Text] [Related]
5. ESR1 and its antagonist fulvestrant in pituitary adenomas.
Gao H; Xue Y; Cao L; Liu Q; Liu C; Shan X; Wang H; Gu Y; Zhang Y
Mol Cell Endocrinol; 2017 Mar; 443():32-41. PubMed ID: 28043824
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas.
Xiao Z; Yang X; Zhang K; Liu Z; Shao Z; Song C; Wang X; Li Z
Int J Med Sci; 2020; 17(18):3174-3189. PubMed ID: 33173437
[TBL] [Abstract][Full Text] [Related]
7. Effects of an estrogen receptor antagonist on proliferation, prolactin secretion and growth factor expression in the MMQ pituitary prolactinoma cell line.
Leng L; Zhang Y
J Clin Neurosci; 2011 Dec; 18(12):1694-8. PubMed ID: 22015101
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of hepatocellular carcinoma by fulvestrant involves the estrogen receptor α and Wnt pathways in vitro and in patients.
Wang CJ; Guo DK; You TG; Shen DW; Wang C; Tang L; Wang J; Xu RH; Zhang H
Mol Med Rep; 2014 Dec; 10(6):3125-31. PubMed ID: 25270093
[TBL] [Abstract][Full Text] [Related]
9. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas.
Li Z; Liu Q; Li C; Zong X; Bai J; Wu Y; Lan X; Yu G; Zhang Y
Mol Cell Endocrinol; 2015 Feb; 402():64-71. PubMed ID: 25578603
[TBL] [Abstract][Full Text] [Related]
10. Expression of estrogen receptor α and growth factors in human prolactinoma and its correlation with clinical features and gender.
Lv H; Li C; Gui S; Zhang Y
J Endocrinol Invest; 2012 Feb; 35(2):174-80. PubMed ID: 21422801
[TBL] [Abstract][Full Text] [Related]
11. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.
Wang S; Wang A; Zhang Y; Zhu K; Wang X; Chen Y; Wu J
BMC Endocr Disord; 2021 Nov; 21(1):235. PubMed ID: 34814904
[TBL] [Abstract][Full Text] [Related]
12. TLR4 inhibition suppresses growth in oestrogen-induced prolactinoma models.
Zhang Y; Ma L; Dong S; Ding Q; Wang S; Wu Q; Ni P; Zhang H; Chen Y; Wu J; Wang X
Endocr Relat Cancer; 2022 Dec; 29(12):703-716. PubMed ID: 36219868
[TBL] [Abstract][Full Text] [Related]
13. Effects of fulvestrant, an estrogen receptor antagonist, on MMQ cells and its mechanism.
Li C; Sun Z; Gui S; Liu F; Zhang Y
Neuro Endocrinol Lett; 2009; 30(2):268-74. PubMed ID: 19675520
[TBL] [Abstract][Full Text] [Related]
14. Pituitary prolactin-secreting tumor formation: recent developments.
Xu RK; Wu XM; Di AK; Xu JN; Pang CS; Pang SF
Biol Signals Recept; 2000; 9(1):1-20. PubMed ID: 10686432
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol inhibited GH3 cell growth and decreased prolactin level via estrogen receptors.
Wang C; Hu ZQ; Chu M; Wang Z; Zhang WG; Wang LZ; Li CG; Wang JS
Clin Neurol Neurosurg; 2012 Apr; 114(3):241-8. PubMed ID: 22104698
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of thalidomide on the growth, secretory function and angiogenesis of estrogen-induced prolactinoma in Fischer 344 rats.
Stepień H; Lawnicka H; Mucha S; Wagrowska-Danilewicz M; Stepień B; Siejka A; Komorowski J
Life Sci; 2006 Sep; 79(18):1741-8. PubMed ID: 16846617
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor antagonist fulvestrant inhibits proliferation and promotes apoptosis of prolactinoma cells by regulating the IRE1/XBP1 signaling pathway.
Wang C; Bai M; Wang X; Tan C; Zhang D; Chang L; Li G; Xie L; Su J; Wen Y
Mol Med Rep; 2018 Oct; 18(4):4037-4041. PubMed ID: 30106152
[TBL] [Abstract][Full Text] [Related]
18. β-Catenin is reduced in membranes of human prolactinoma cells and it is inhibited by temozolomide in prolactin secreting tumor models.
Demarchi G; Valla S; Perrone S; Chimento A; Bonadeo N; Vitale DL; Spinelli FM; Cervio A; Sevlever G; Alaniz L; Berner S; Cristina C
Tumour Biol; 2022; 44(1):85-105. PubMed ID: 35811548
[TBL] [Abstract][Full Text] [Related]
19. Letrozole Decreased Testosterone-Induced Cell Proliferation and Prolactin Secretion also Increased Apoptosis in MMQ and GH3 Rat Prolactinoma Cell Lines.
Selek A; Halbutoğulları ZSU; Aydemir Çİ; Cetinarslan B; Canturk Z; Tarkun I; Erman G; Subaşı C; Erdal K
Mol Neurobiol; 2023 May; 60(5):2442-2454. PubMed ID: 36662360
[TBL] [Abstract][Full Text] [Related]
20. Different epigenetic mechanisms of ERα implicated in the fate of fulvestrant-resistant breast cancer.
Tsuboi K; Kaneko Y; Nagatomo T; Fujii R; Hanamura T; Gohno T; Yamaguchi Y; Niwa T; Hayashi SI
J Steroid Biochem Mol Biol; 2017 Mar; 167():115-125. PubMed ID: 27888136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
